secwatch.observer — SEC 8-K summary
======================================

Issuer:     TriSalus Life Sciences, Inc. (TLSI)
CIK:        0001826667
Form:       8-K
Filed at:   2022-12-02T23:59:59+00:00
Accession:  0001104659-22-124148
Event type: debt
Sentiment:  neutral
Materiality: 0.35
Item codes: 1.01, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MedTech Acquisition amends $944K sponsor notes; principal waived if no business combination
--------------------------------------------------------------------------------

- Amended two promissory notes ($544K and $400K) to clarify principal not payable if initial business combination not completed by 24-month IPO anniversary or extended date.
- Amendment eliminates repayment obligation upon failure to close a deal; all other terms unchanged.
- Notes were issued to sponsor MedTech Acquisition Sponsor LLC for working capital.
- Amendment effective December 2, 2022; notes originally issued December 30, 2021 and January 28, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1826667/000110465922124148/0001104659-22-124148-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1826667/000110465922124148/tm2231921d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-124148

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer